retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Retatrutide: The "Triple G" Peptide That Could Rival Bariatric Surgery (And Why You Shouldn't Wait) Full Retatrutide data just presented

This section will briefly review what we know about the current safety data of GLP-1 and GLP-1/GIP agonists, and factors that may promote long term clinical use of these agents in obesity

Researchers comparing non-incretin options can also review the tesofensine protocol and SLU-PP-332 protocol

Personalized Care with GLP-1 Therapy Compounding GLP-1 compounding refers to the process of creating customized formulations of glucagon-like peptide-1 (GLP-1) receptor agonists by compounding pharmacies

It is a 39-amino acid synthetic peptide engineered from a GIP backbone to activate three distinct receptor systems in the body

As a dietary supplement, it does not require FDA approval before sale